Inovio possesses a critical asset in the expertise of its senior management team, Board of Directors, and Scientific Advisory Board. The ability for Inovio to complete its mission of transforming medicine through the development of synthetic immunotherapies will depend upon the people guiding and executing Inovio’s business plan. Management is comprised of highly experienced individuals with entrepreneurial as well as big pharma experience across many facets of the biotech and pharmaceutical industries. Chief Executive Dr. Joseph Kim’s vision and enthusiasm has persuaded top business and medical professionals to join him in guiding Inovio. Among them are luminaries in medicine, business and science, such as Dr. David Weiner, recognized as the “father of DNA vaccines,” and other senior scientists, such as the developer of the rubella vaccine; and senior pharmaceutical and biotech executives and leaders with international expertise in bringing new vaccines through the regulatory process to commercialization.